Could a diabetes drug be the key to slowing Parkinson's?
NCT ID NCT04232969
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether exenatide, a drug already used for type 2 diabetes, can slow the progression of Parkinson's disease. About 194 people with early-stage Parkinson's received either exenatide or a placebo once a week for two years. The goal was to see if the drug could protect nerve cells and reduce worsening of movement and other symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University College London Hospital
London, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- High-Resolution brain scans aim to unmask Tau's role in Parkinson's
- Can brain stimulation sharpen Decision-Making in Parkinson's?
- Can Stem-Cell implants restore movement in Parkinson's?
- Wild blueberries put to the test for Parkinson's motor symptoms
- Could tailored brain stimulation quiet Parkinson's tremors more effectively?
- Zapping away tremors: scientists probe how electrical stimulation calms shaky hands